Feasibility Study of a Transition Pathway at Discharge From Full Hospitalization in Oncology (PATROL)

Etude de faisabilité d'un Parcours de Transition à la Sortie d'Hospitalisation complète en Oncologie - Etude Pilote Monocentrique

Patient reported outcomes (PRO) measure the health status directly reported by the patients, without external interpretation, generally collected using self-questionnaires, including online tools (ePRO). This approach is useful in early detection of signs of relapse, with reduced anxiety, improved quality of life and survival, and reduced readmissions to emergency departments in patients with advanced cancer. In the current context where hospitalization is increasingly short, the transition from hospital to home is a critical moment that poses a significant safety challenge Patient follow-up strategies help patients return home, particularly in surgery, with telephone calls from a nurse the day after or several days after discharge. In oncology, telephone calls from the pharmacist 3 days after discharge from hospital helped to identify undesirable effects of treatments. In general medicine, these calls have led to improved patient satisfaction, reduced use of emergency departments and the resolution of drug-related problems, but are costly. The introduction of post-hospitalization ePRO monitoring in oncology could ensure effective follow-up while keeping costs under control. A coordinating nurse could manage this process and play a crucial role in accompanying patients when they return home.

The study authors aimed to evaluate the feasibility of a transitional nurse consultation and ePRO follow-up on discharge from full hospitalization in oncology in this population of frail and elderly patients.

Study Overview

• Status: Recruiting
• Conditions: Cancer
• Intervention / Treatment: Other: OncoCare transition program

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Astrid Basset; Phone Number: 06.24.89.63.27; Email: astrid.basset@chu-nimes.fr

Study Locations

• France
  • Nîmes, France, 30000
    • Recruiting
    • Centre Hospitalier de Nîmes
    • Sub-Investigator: Frédéric Fiteni
    • Contact: Anissa Megzari, Doctor; Phone Number: 04.66.68.42.36; Email: drc@chu-nimes.fr
    • Principal Investigator: Astrid Basset
    • Sub-Investigator: Pauline Vazquez
    • Sub-Investigator: Bruno Beudot

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Consecutive patients treated as inpatients in the Medical Oncology Department of Nîmes University Hospital and scheduled to be discharged and returned home.

Description

Inclusion Criteria:

• The patient must have given their free and informed consent and signed the consent form
• The patient must be a member or beneficiary of a health insurance plan
• Adult patient hospitalized in an oncology unit for at least 48 hours.
• Patient capable of using a connected device, in possession of a smartphone or tablet, and with an internet connection at home.
• Patient discharged from hospital to go home.

Exclusion Criteria:

• The patient is in a period of exclusion determined by a previous study
• The subject refuses to sign the consent
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship
• Patient considered to be at the end of life.
• Patient unable to read and understand French
• Patient discharged from hospitalization to a home care facility
• Patient having been hospitalized in a full-time inpatient setting for a scheduled procedure (chemotherapy or interventional procedure)
• Pregnant, parturient, or breastfeeding

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Compliance with ePRO monitoring	Percentage of patients who responded to all questionnaires	Day 2
Compliance with the telephone call at day 7	Percentage of patients successfully contacted at day 7	Day 7
Patient satisfaction with the care pathway	Question: "Are you satisfied with your care pathway?" (Yes/no)	Day 15

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of the transition pathway to home	Care Transitions Measure (CTM-3) questionnaire, where a 10-point increase reduces the risk of readmission by 14%	Day 15
Quality of life as reported by the patient	EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.	Day 0
Quality of life as reported by the patient	EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.	Day 7
Quality of life as reported by the patient	EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.	Day 15
Quality of life as reported by the patient	EORTC QLQ-C30 questionnaire: The score for each subscale ranges from 0 to 100and good quality of life is associated with a high score on the functional scales and a low score on the symptom scales.	Day 30
Patient satisfaction with their care	EORTC PATSAT-C33 questionnaire: The total score ranges from 0 to 100	Day 15
Rate of readmissions to a healthcare facility	Rate of readmissions to healthcare establishments (hospitalization department, emergency room)	One month after hospitalization

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de Nīmes
• Investigators: Principal Investigator: Astrid Basset, CHU de Nîmes

Study record dates

Study Major Dates

• Study Start (Estimated): March 1, 2026
• Primary Completion (Estimated): December 1, 2028
• Study Completion (Estimated): December 1, 2028

Study Registration Dates

• First Submitted: November 20, 2025
• First Submitted That Met QC Criteria: November 20, 2025
• First Posted (Actual): December 1, 2025

Study Record Updates

• Last Update Posted (Actual): January 28, 2026
• Last Update Submitted That Met QC Criteria: January 26, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: NIMAO/2023-2/AB01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No